Statins in the prevention of dementia and Alzheimer's disease: A meta-analysis of observational studies and an assessment of confounding

Pharmacoepidemiology and Drug Safety

Volumn 22, Issue 4, 2013, Pages 345-358

  Wong, William B ^a,b   Lin, Vincent W ^a   Boudreau, Denise ^a,c   Devine, Emily Beth ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b ALLERGAN INC   (United States)

^c GROUP HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

Alzheimer's disease; Dementia; Healthy user bias; Meta analysis; Observational study; Pharmacoepidemiology; Statins

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ALZHEIMER DISEASE; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONFOUNDING VARIABLE; CROSS-SECTIONAL STUDY; DEMENTIA; EXPLORATORY RESEARCH; HUMAN; LIPOPHILICITY; LONGITUDINAL STUDY; META ANALYSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; STUDY DESIGN; SYSTEMATIC REVIEW;

ALZHEIMER DISEASE; DEMENTIA; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84875805775     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3381     Document Type: Article

References (45)

1. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 2004; 110(2): 227-239. DOI: 10.1161/01.CIR.0000133317.49796.0E
2. Alzheimer's Association. Alzheimer's disease facts and figures. 2010.
3. Kandiah N, Feldman HH. Therapeutic potential of statins in alzheimer's disease. J Neurol Sci 2009; 283(1-2): 230-234. DOI: 10.1016/j.jns.2009.02.352
4. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 2000; 57(10): 1439-1443.
5. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA. Statins and the risk of dementia. Lancet 2000; 356(9242): 1627-1631.
6. Rea TD, Breitner JC, Psaty BM, et al. Statin use and the risk of incident dementia: The cardiovascular health study. Arch Neurol 2005; 62(7):1047-1051. DOI: 10.1001/archneur.62.7.1047
7. Reitz C, Tang MX, Luchsinger J, Mayeux R. Relation of plasma lipids to alzheimer disease and vascular dementia. Arch Neurol 2004; 61(5): 705-714. DOI: 10.1001/archneur.61.5.705
8. Li G, Higdon R, Kukull WA, et al. Statin therapy and risk of dementia in the elderly: A community-based prospective cohort study. Neurology 2004; 63(9): 1624-1628.
9. Zandi PP, Sparks DL, Khachaturian AS, et al. Do statins reduce risk of incident dementia and alzheimer disease? the cache county study. Arch Gen Psychiatry 2005; 62(2): 217-224. DOI: 10.1001/archpsyc.62.2.217
10. Etminan M, Gill S, Samii A. The role of lipid-lowering drugs in cognitive function: A meta-analysis of observational studies. Pharmacotherapy 2003; 23(6): 726-730.
11. Zhou B, Teramukai S, Fukushima M. Prevention and treatment of dementia or alzheimer's disease by statins: A meta-analysis. Dement Geriatr Cogn Disord 2007; 23(3): 194-201. DOI: 10.1159/000099037
12. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009; (2)(2): CD003160. DOI: 10.1002/14651858.CD003160.pub2
13. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20, 536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360(9326): 7-22. DOI: 10.1016/S0140-6736(02)09327-3
14. Trompet S, van Vliet P, de Craen AJ, et al. Pravastatin and cognitive function in the elderly. results of the PROSPER study. J Neurol 2010; 257(1): 85-90. DOI: 10.1007/s00415-009-5271-7
15. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In Systematic reviews in health care. BMJ Publishing Group: London, UK, 2001; 2008: 285-312. DOI: 10.1002/9780470693926.ch15
16. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-188.
17. Robins J, Breslow N, Greenland S. Estimators of the mantel-haenszel variance consistent in both sparse data and large-strata limiting models. Biometrics 1986; 42(2): 311-323.
18. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of dementia in the united states: The aging, demographics, and memory study. Neuroepidemiology 2007; 29(1-2): 125-132. DOI: 10.1159/000109998
19. Symons MJ, Moore DT. Hazard rate ratio and prospective epidemiological studies. J Clin Epidemiol 2002; 55(9): 893-899.
20. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-1558. DOI: 10.1002/sim.1186
21. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003; 327(7414): 557-560. DOI: 10.1136/bmj.327.7414.557
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-634.
23. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and parkinson's disease. BMC Med 2007; 5: 20. DOI: 10.1186/1741-7015-5-20
24. Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in england and wales: Population based cohort study using the QResearch database. BMJ 2010; 340: c2197. DOI: 10.1136/bmj.c2197
25. Golder S, Loke YK, Bland M. Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: Methodological overview. PLoS Med 2011; 8(5): e1001026. DOI: 10.1371/journal.pmed.1001026
26. Lai JK, Lucas RM, Clements MS, Roddam AW, Banks E. Hip fracture risk in relation to vitamin D supplementation and serum 25-hydroxyvitamin D levels: A systematic review and meta-analysis of randomised controlled trials and observational studies. BMC Public Health 2010; 10: 331. DOI: 10.1186/1471-2458-10-331
27. Shrier I, Boivin JF, Steele RJ, et al. Should meta-analyses of interventions include observational studies in addition to randomized controlled trials? A critical examination of underlying principles. Am J Epidemiol 2007; 166(10): 1203-1209. DOI: 10.1093/aje/kwm189
28. Bettermann K, Arnold AM, Williamson J, et al. Statins, risk of dementia, and cognitive function: Secondary analysis of the ginkgo evaluation of memory study. J Stroke Cerebrovasc Dis 2011. DOI: 10.1016/j.jstrokecerebrovasdis.2010.11.002
29. Beydoun MA, Beason-Held LL, Kitner-Triolo MH, et al. Statins and serum cholesterol's associations with incident dementia and mild cognitive impairment. J Epidemiol Community Health 2011; 65(11): 949-957. DOI: 10.1136/jech.2009.100826
30. Smeeth L, Douglas I, Hall AJ, Hubbard R, Evans S. Effect of statins on a wide range of health outcomes: A cohort study validated by comparison with randomized trials. Br J Clin Pharmacol 2009; 67(1): 99-109. DOI: 10.1111/j.1365-2125.2008.03308.x
31. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology 2008; 71(5): 344-350. DOI: 10.1212/01.wnl.0000319647.15752.7b
32. Szwast SJ, Hendrie HC, Lane KA, et al. Association of statin use with cognitive decline in elderly african americans. Neurology 2007; 69(19): 1873-1880. DOI: 10.1212/01.wnl.0000279333.77404.d7
33. Li G, Shofer JB, Rhew IC, et al. Age-varying association between statin use and incident alzheimer's disease. J Am Geriatr Soc 2010; 58(7): 1311-1317. DOI: 10.1111/j.1532-5415.2010.02906.x
34. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. Statins are associated with a reduced risk of alzheimer disease regardless of lipophilicity. the rotterdam study. J Neurol Neurosurg Psychiatry 2009; 80(1): 13-17. DOI: 10.1136/jnnp.2008.150433
35. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res 2008; 5(4): 416-421.
36. Arvanitakis Z, Schneider JA, Wilson RS, et al. Statins, incident alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008; 70(19 Pt 2): 1795-1802. DOI: 10.1212/01.wnl.0000288181.00826.63
37. Zigman WB, Schupf N, Jenkins EC, Urv TK, Tycko B, Silverman W. Cholesterol level, statin use and alzheimer's disease in adults with down syndrome. Neurosci Lett 2007; 416(3): 279-284. DOI: 10.1016/j.neulet.2007.02.023
38. Green RC, McNagny SE, Jayakumar P, et al. Statin use and the risk of alzheimer's disease: The MIRAGE study. Alzheimers Dement 2006; 2(2): 96-103. DOI: 10.1016/j.jalz.2006.02.003
39. Zamrini E, McGwin G, Roseman JM. Association between statin use and alzheimer's disease. Neuroepidemiology 2004; 23(1-2): 94-98. DOI: 10.1159/000073981
40. Dufouil C, Richard F, Fievet N, et al. APOE genotype, cholesterol level, lipid-lowering treatment, and dementia: The three-city study. Neurology 2005; 64(9): 1531-1538. DOI: 10.1212/01.WNL.0000160114.42643.31
41. Hajjar I, Schumpert J, Hirth V, Wieland D, Eleazer GP. The impact of the use of statins on the prevalence of dementia and the progression of cognitive impairment. J Gerontol A Biol Sci Med Sci 2002; 57(7): M414-8.
42. Rockwood K, Kirkland S, Hogan DB, et al. Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 2002; 59(2): 223-227.
43. Rodriguez EG, Dodge HH, Birzescu MA, Stoehr GP, Ganguli M. Use of lipid-lowering drugs in older adults with and without dementia: A community-based epidemiological study. J Am Geriatr Soc 2002; 50(11): 1852-1856.
44. Fillit H, Geldmacher DS, Welter RT, Maslow K, Fraser M. Optimizing coding and reimbursement to improve management of alzheimer's disease and related dementias. J Am Geriatr Soc 2002; 50(11): 1871-1878.
45. Glynn RJ, Schneeweiss S, Wang PS, Levin R, Avorn J. Selective prescribing led to overestimation of the benefits of lipid-lowering drugs. J Clin Epidemiol 2006; 59(8): 819-828. DOI: 10.1016/j.jclinepi.2005.12.012